

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

November 14, 2017

Listing Department  
**BOMBAY STOCK EXCHANGE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

**Code: 532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: CADILAHC**

**Re: Press Release**

Dear Sir,

We are forwarding herewith a copy of press release proposed to be published in the newspapers in the matter of unaudited financial results for the quarter / half year ended on September 30, 2017 the same may please receive in order.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**



**UPEN H. SHAH**  
**COMPANY SECRETARY**

Encl.: As above

## Zydus Cadila's EBIDTA up by 68% in Q2

Ahmedabad, November 14, 2017

For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 857 crores, up by 68% y-o-y. The total income from operations was up by 35% y-o-y to Rs. 3,234 crores and net profit was up 33% to Rs. 503 crores.

The company's business in the US posted sales of Rs. 1,644 crores, up by 66%. During the quarter, the company launched 4 new products in the US including Mesalamine Delayed Release 1.2 g tablets (generic version of Lialda ®) with a 180 days exclusivity and received approval for 32 new products, including the generic version of Asacol ® HD (Mesalamine DR 800 mg tablets) and the generic version of Tamiflu ® suspension (Oseltamivir Powder for Oral Suspension 6 mg/ ml). The company filed 9 additional ANDAs with the USFDA, during the quarter.

The India formulations business posted sales of Rs. 895 crores, up by 15% excluding the excise duty. The company launched 25 new products including line extensions in India during the quarter with 5 first in India launches. The company's business in the emerging markets grew by 16%.

Furthering its innovation programme, the company announced the initiation of a phase II trial investigating ZYANI, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anemia associated with chronic kidney disease (CKD), during the quarter.

\*\*\*